<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Supraventricular arrhythmias after myocardial infarction</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Supraventricular arrhythmias after myocardial infarction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Supraventricular arrhythmias after myocardial infarction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Spragg, MD, FHRS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kapil Kumar, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brian Olshansky, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James Hoekstra, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Supraventricular arrhythmias, other than atrial fibrillation (AF) or flutter, are relatively uncommon in the periinfarction period. Their occurrence often indicates myocardial dysfunction and they may, by themselves, cause congestive heart failure or exacerbate ongoing myocardial ischemia.</p><p>The incidence, mechanism, and treatment of supraventricular arrhythmias (particularly sinus bradycardia, sinus tachycardia, and AF) occurring after myocardial infarction (MI) will be reviewed here. The focus of the discussion here is on supraventricular arrhythmias in the setting of MI caused by acute atherothrombotic coronary artery disease. However, there are some clinical settings in which supraventricular arrhythmia may cause MI (such as when AF causes left atrial thrombus that embolizes to a coronary artery, or in the setting of a supraventricular tachycardia causing demand ischemia and MI). (See  <a class="medical medical_review" href="/d/html/52.html" rel="external">"Diagnosis of acute myocardial infarction"</a> and  <a class="medical medical_review" href="/d/html/52.html" rel="external">"Diagnosis of acute myocardial infarction", section on 'Definitions'</a>.)</p><p>The following related topics are discussed separately: conduction disturbances after MI, ventricular arrhythmias during MI, and risk stratification of patients after MI. (See  <a class="medical medical_review" href="/d/html/45.html" rel="external">"Conduction abnormalities after myocardial infarction"</a> and  <a class="medical medical_review" href="/d/html/1060.html" rel="external">"Ventricular arrhythmias during acute myocardial infarction: Incidence, mechanisms, and clinical features"</a> and  <a class="medical medical_review" href="/d/html/78.html" rel="external">"Risk stratification after acute ST-elevation myocardial infarction"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">SINUS BRADYCARDIA</span><span class="headingEndMark"> — </span>Sinus bradycardia, defined as less than 50 to 60 beats per minute (bpm), occurs in 15 to 25 percent of patients after acute MI [<a href="#rid1">1-3</a>]. It has the following clinical characteristics [<a href="#rid1">1,2,4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>It is frequently seen with inferior wall infarctions, since the right coronary artery supplies the sinoatrial node (SA) in approximately 60 percent of people.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is most often transient, particularly for sinus bradycardia occurring within the first six hours; such arrhythmias typically resolve within 24 hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is usually caused by increased vagal tone, often seen with inferior MI. In some cases, this may be the result of diaphragmatic irritation. Other less common causes include ischemia of the SA node and as a reperfusion arrhythmia following fibrinolysis [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is due to medications (beta blockade, calcium channel blocker, or <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a>).</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>If therapy is necessary due to hemodynamic compromise or ischemia, sinus bradycardia following an acute MI usually responds well to intravenous <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a> (0.6 to 1.0 mg in the majority of cases) [<a href="#rid6">6,7</a>]. Persistent bradycardia with hemodynamic compromise despite intravenous atropine warrants consideration of temporary cardiac pacing [<a href="#rid6">6,7</a>]. Atrial or sequential atrioventricular (AV) pacing is superior to ventricular pacing, particularly if there is an associated right ventricular MI [<a href="#rid8">8</a>].</p><p>Permanent pacing is not typically necessary in patients with sinus bradycardia after an MI, because in most cases the bradyarrhythmia is transient [<a href="#rid7">7</a>]. Any decision to implant a permanent cardiac pacemaker should be delayed for several days of observation. (See  <a class="medical medical_review" href="/d/html/941.html" rel="external">"Permanent cardiac pacing: Overview of devices and indications"</a>.)</p><p>Mortality as a result of periinfarction sinus bradycardia is rare [<a href="#rid1">1</a>]. Its significance is related to the associated reduction in cardiac output and coronary perfusion, thereby exacerbating ischemia, and to the possible development of an escape rhythm with possible AV dissociation causing hemodynamic compromise [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H4"><span class="h1">SINUS TACHYCARDIA</span><span class="headingEndMark"> — </span>Sinus tachycardia occurs in approximately 30 to 40 percent of acute MIs [<a href="#rid10">10</a>]. Although this is seen on presentation, the heart rate usually declines over time to a level that reflects the degree of activation of the sympathetic nervous system. Patients with persistent sinus tachycardia usually have larger infarcts that are more often anterior [<a href="#rid10">10</a>] and a marked impairment in left ventricular (LV) function, which is associated with substantial morbidity, a high early mortality, and an increased 30-day mortality [<a href="#rid10">10,11</a>]. In addition, sinus tachycardia may increase the size of ischemic injury and infarction due at least in part to increased oxygen consumption. In some cases, sinus tachycardia may be the result of associated pericarditis.</p><p>Therapeutic efforts should be targeted at identification and management of the underlying cause. However, most patients will receive such therapy independent of the tachycardia since early beta blocker administration is part of routine management of acute MI. Care should be exercised in the utilization of beta blockers early in an infarction, especially in the presence of large anterior MIs, hypotension, or pulmonary congestion. (See  <a class="medical medical_review" href="/d/html/96.html" rel="external">"Acute myocardial infarction: Role of beta blocker therapy"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">ATRIAL FIBRILLATION</span><span class="headingEndMark"> — </span>The following section will review the incidence, pathophysiology, clinical characteristics, and treatment of the atrial tachyarrhythmias that occur after acute MI. AF is the most common of these.</p><p>The overall incidence of atrial tachyarrhythmias in the periinfarction period ranges from 6 to 20 percent [<a href="#rid9">9,10,12-17</a>]. These arrhythmias primarily occur within the first 72 hours after infarction; however, only 3 percent are noted in the very early (less than three-hour) phase [<a href="#rid12">12</a>].</p><p>AF is common both during hospitalization and after discharge for acute MI and in both time periods has prognostic significance. The incidence during hospitalization has been reported to be between 5 and 18 percent and is more likely in individuals with heart failure, kidney disease, hypertension, diabetes, and pulmonary disease [<a href="#rid13">13,14,18</a>]. As expected with these risk factors, 30-day mortality in patients who develop AF is increased [<a href="#rid13">13</a>]. Long-term mortality is also increased in patients with in-hospital AF compared to those without [<a href="#rid9">9,13,15,16,19-22</a>].</p><p>Information concerning the longer-term incidence and prognosis of patients who develop AF after discharge comes from the CARISMA study, which evaluated the long-term development of arrhythmias in 271 patients with acute MI and an LV ejection fraction less than 40 percent [<a href="#rid18">18</a>]. These individuals underwent placement of an insertable cardiac monitor (ICM; also sometimes referred to as implantable cardiac monitor or implantable loop recorder) and were monitored for the development of AF lasting more than 16 beats. (See  <a class="medical medical_review" href="/d/html/958.html" rel="external">"Ambulatory ECG monitoring", section on 'Insertable cardiac monitor'</a> and  <a class="medical medical_review" href="/d/html/1060.html" rel="external">"Ventricular arrhythmias during acute myocardial infarction: Incidence, mechanisms, and clinical features", section on 'Late arrhythmias'</a>.)</p><p>The following findings were noted during two years of follow-up:</p><p class="bulletIndent1"><span class="glyph">●</span>Ninety-five individuals (39 percent) developed AF. Nearly half of these occurred by two months and nearly 80 percent by one year. Most of the AF events were asymptomatic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The duration of the AF event(s) was more than 30 seconds in slightly more than half of these.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>New onset AF was associated with a significantly increased risk of major cardiovascular events (Unadjusted hazard ratio [HR] 2.04). AF remained a significant predictor of adverse outcomes even after adjustment. The risk was significantly increased in those individuals whose duration of AF was more than 30 seconds (HR 2.73, 95% CI 1.25-5.50), but not in those with episodes lasting less than 30 seconds (HR 1.17, 95% CI 0.35-3.92).</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Pathophysiology</span><span class="headingEndMark"> — </span>The increase in the prevalence of AF during an acute MI has been ascribed to one or more of the following factors: atrial dysfunction (due to atrial ischemia, which is rare; infarction, which is rare; or atrial stretching due to heart failure with elevation in left atrial pressures, which is the most common etiology) [<a href="#rid23">23</a>], sympathetic stimulation, pericarditis [<a href="#rid24">24</a>], inflammatory state [<a href="#rid25">25</a>], atheromatous disease of the arteries supplying the sinoatrial (SA) and AV nodes and the left atrium (which is a rare cause for AF) [<a href="#rid10">10,12,21,26</a>], and iatrogenic factors such as positive inotropic agents.</p><p class="headingAnchor" id="H6069741"><span class="h2">Prevention</span><span class="headingEndMark"> — </span>Statin therapy, possibly due to an antiinflammatory effect, has been associated with a reduction in AF recurrences in patients with lone AF, ischemic heart disease, and after cardiac bypass surgery. (See  <a class="medical medical_review" href="/d/html/1038.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials", section on 'Statins'</a>.)</p><p>In a retrospective study of over 3300 patients presenting with acute MI and in sinus rhythm, statin therapy (prescription within 48 hours of hospitalization) was associated with a reduced risk of AF (odds ratio 0.64, 95% CI 0.45-0.92) [<a href="#rid27">27</a>].</p><p>However, we do not recommend initiation of statin therapy in patients with MI to solely prevent AF. Almost all such patients should be on statin therapy for other reasons. (See  <a class="medical medical_review" href="/d/html/100.html" rel="external">"Low-density lipoprotein-cholesterol (LDL-C) lowering after an acute coronary syndrome", section on 'Summary and recommendations'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The management of periinfarction atrial tachyarrhythmias is important, because tachycardia can increase myocardial oxygen demand, thereby exacerbating ischemia and possibly decreasing cardiac output. Atrial tachyarrhythmias may also induce or exacerbate heart failure, especially when associated with a rapid ventricular response. For sustained AF or atrial flutter that is of new onset after the MI and is associated with hemodynamic compromise, we make the following recommendations:</p><p class="bulletIndent1"><span class="glyph">●</span>Initial treatment should consist of rate control. The first-line treatment is beta blockade. One option is intravenous <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> (2.5 to 5.0 mg every two to five minutes to a total of 15 mg over 10 to 15 minutes). If ineffective, intravenous calcium channel blockade (<a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> or <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>) should be considered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For unstable patients, synchronized direct current cardioversion should be considered. (See  <a class="medical medical_review" href="/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion"</a> and  <a class="medical medical_review" href="/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion", section on 'Indications'</a>.)</p><p></p><p class="bulletIndent1">For episodes of AF with hemodynamic compromise that do not respond to electrical cardioversion or that recur after a brief period of sinus rhythm, the use of intravenous followed by oral <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> to help control rate and help maintain sinus is indicated.</p><p></p><p class="bulletIndent1">The use of <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> or <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> in the setting of hemodynamic compromise is recommended because these drugs are associated with less risk of worsening myocardial dysfunction than some other drugs (although some preparations of intravenous amiodarone can cause hypotension, which is the result of Tween 80, the detergent used to get amiodarone into aqueous solution) and have not been associated with increased risk of mortality post-infarction. However, in many patients hemodynamic compromise during AF is a result of the rapid ventricular rate. In such cases, amiodarone and digoxin, which slow AV conduction only gradually and after a long period of time, may not be as effective as other agents. We recommend the use of either an intravenous beta blocker or intravenous <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> in this setting.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8904" href="/d/drug information/8904.html" rel="external">Dofetilide</a> is also an effective drug for long-term management of AF after MI to help maintain sinus rhythm. The DIAMOND-MI trial found that this drug had no effect on all-cause, cardiac, or total arrhythmic mortality compared to placebo [<a href="#rid28">28</a>]. However, dofetilide was better than placebo for reverting AF or flutter to sinus rhythm (42.3 versus 12.5 percent for placebo).</p><p></p><p>For patients with sustained AF or atrial flutter without ongoing ischemia or hemodynamic compromise, rate control is indicated. Consideration should be given to cardioversion to sinus rhythm in patients without a history of AF or atrial flutter prior to MI. (See  <a class="medical medical_review" href="/d/html/938.html" rel="external">"Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"</a> and  <a class="medical medical_review" href="/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p>Long-term antiarrhythmic therapy may not be necessary if factors associated with recurrent AF, such as moderate to severe LV systolic dysfunction or heart failure, are absent [<a href="#rid16">16,22,29</a>]. We suggest reassessment of the patient’s rhythm status in one to two months after MI. If there is no evidence of recurrent AF and if risk factors for recurrence are absent, antiarrhythmic therapy can be discontinued.</p><p>The role of anticoagulation in these patients is discussed elsewhere. (See <a class="local">'Anticoagulation'</a> below and  <a class="medical medical_review" href="/d/html/906.html" rel="external">"Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"</a>.)</p><p class="headingAnchor" id="H446714404"><span class="h3">Anticoagulation</span><span class="headingEndMark"> — </span>The optimal anticoagulation strategy for patients with MI who develop AF for the first time is unknown.</p><p>With regard to intravenous heparin, most of our experts use it in patients who will be cardioverted prior to discharge. For patients who will not be cardioverted, some of our experts use intravenous heparin until such time as the patient is successfully anticoagulated with an oral agent while others do not use heparin (particularly in patients with a low CHA<sub>2</sub>DS-VASc score) prior to oral anticoagulation. Most of our experts recommend at least three to four weeks of oral anticoagulant, assuming the patient is not at high bleeding risk. (See  <a class="medical medical_review" href="/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants", section on 'Summary and recommendations'</a>.)</p><p>For those patients who are discharged on anticoagulant therapy after one episode of AF, the optimal duration is unknown [<a href="#rid30">30</a>]. As the risk of bleeding is very high in patients on triple antithrombotic therapy (ie, antiplatelet therapy for those receive a stent along with anticoagulation), practitioners should carefully and repeatedly reassess the need for continued anticoagulation (and thienopyridine). This issue is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy"</a>.)</p><p>Patients with recurrent episodes of AF, especially if persistent or permanent (which is often the result of LV dysfunction and heart failure post-MI), should be treated with oral anticoagulants long term. (See  <a class="medical medical_review" href="/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation", section on 'Classification and terminology'</a> and  <a class="medical medical_review" href="/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a> and  <a class="medical medical_review" href="/d/html/101.html" rel="external">"Acute coronary syndrome: Oral anticoagulation in medically treated patients"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">PSVT</span><span class="headingEndMark"> — </span>Paroxysmal supraventricular tachycardia (PSVT) occurs in less than 10 percent of patients after an acute MI, but may require aggressive management due to a rapid ventricular rate [<a href="#rid31">31</a>]. We suggest the following sequence of therapeutic measures [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Carotid sinus massage or a valsalva maneuver (both of which increase vagal tone and alter AV nodal properties). (See  <a class="medical medical_review" href="/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation", section on 'Carotid sinus massage'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a> (6 mg over one to two seconds; if no response, 12 mg one to two minutes later; may repeat 12 mg dose if needed). We suggest adenosine be used only in patients who have been revascularized. An external defibrillator should be available since a small percentage of patients develop ventricular fibrillation from adenosine likely related to a coronary steal phenomenon.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous beta blockade with <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> (2.5 to 5.0 mg every two to five minutes to a total of 15 mg over 10 to 15 minutes) or <a class="drug drug_general" data-topicid="9420" href="/d/drug information/9420.html" rel="external">esmolol</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Our authors and reviewers also suggest that either intravenous <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>, <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>, or cardioversion may be considered.</p><p></p><p class="headingAnchor" id="H12"><span class="h1">NONPAROXYSMAL JUNCTIONAL TACHYCARDIA</span><span class="headingEndMark"> — </span>Junctional tachycardia (or an accelerated junctional tachycardia) is an arrhythmia arising from a discrete focus within the AV node or His bundle. The mechanism is thought to be one of enhanced automaticity rather than reentry. In adults, this rhythm, generally called nonparoxysmal junctional tachycardia, and is an uncommon arrhythmia associated with acute MI [<a href="#rid32">32-34</a>]. The same arrhythmia may also be seen with digitalis intoxication [<a href="#rid35">35,36</a>].</p><p>Atrial activity during junctional tachycardia is variable. Retrograde atrial activation may occur, with a P wave that either follows each QRS complex or is concealed in the QRS complex, as with AV nodal reentrant tachycardia. If retrograde conduction does not occur, independent atrial activity may be seen, with complete AV dissociation that must be distinguished from AV dissociation due to complete heart block (in complete heart block, the atrial rate exceeds the ventricular rate, while with an accelerated junctional tachycardia the atrial rate is slower than the ventricular rate). (See  <a class="medical medical_review" href="/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation", section on 'Undetectable P waves'</a>.)</p><p>Nonparoxysmal junctional tachycardia is typically transient, occurring within the first 48 hours of infarction and developing and terminating gradually. The rate of a junctional tachycardia is generally slightly above 100 bpm, whereas reentrant paroxysmal supraventricular tachycardias (PSVTs) are generally faster. No specific antiarrhythmic therapy is indicated [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H3871549812"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114034.html" rel="external">"Society guideline links: Non-ST-elevation acute coronary syndromes (non-ST-elevation myocardial infarction)"</a> and  <a class="medical medical_society_guidelines" href="/d/html/113180.html" rel="external">"Society guideline links: ST-elevation myocardial infarction (STEMI)"</a>.)</p><p class="headingAnchor" id="H701771643"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Supraventricular arrhythmias, other than atrial fibrillation (AF) or atrial flutter, are relatively uncommon in the periinfarction period.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The incidence of in-hospital AF after myocardial infarction (MI) ranges from 5 to 18 percent. The development of AF is associated with a worse prognosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sinus bradycardia, defined as less than 50 to 60 beats per minute, occurs in 15 to 25 percent of patients after acute MI and is most often due to increased vagal tone. (See <a class="local">'Sinus bradycardia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sinus tachycardia occurs in approximately 30 to 40 percent of acute MIs. Patients with persistent sinus tachycardia usually have larger infarcts that are more often anterior, associated with a marked impairment in left ventricular function, and a high, early, and 30-day mortality. (See <a class="local">'Sinus tachycardia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Paroxysmal supraventricular tachycardia (PSVT) occurs in less than 10 percent of patients after an acute MI, but may require aggressive management due to a rapid ventricular rate. (See <a class="local">'PSVT'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonparoxysmal junctional tachycardia is typically transient, occurring within the first 48 hours of infarction and developing and terminating gradually. No specific antiarrhythmic therapy is indicated.</p><p></p><p class="headingAnchor" id="H621890796"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Philip J Podrid, MD, FACC, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Marks R, Beard RJ, Clark ML, et al. Gastrointestinal observations in rosacea. Lancet 1967; 1:739.</a></li><li><a class="nounderline abstract_t">Adgey AA, Geddes JS, Mulholland HC, et al. Incidence, significance, and management of early bradyarrhythmia complicating acute myocardial infarction. Lancet 1968; 2:1097.</a></li><li><a class="nounderline abstract_t">Rotman M, Wagner GS, Wallace AG. Bradyarrhythmias in acute myocardial infarction. Circulation 1972; 45:703.</a></li><li><a class="nounderline abstract_t">Zimetbaum PJ, Josephson ME. Use of the electrocardiogram in acute myocardial infarction. N Engl J Med 2003; 348:933.</a></li><li><a class="nounderline abstract_t">Goldberg S, Greenspon AJ, Urban PL, et al. Reperfusion arrhythmia: a marker of restoration of antegrade flow during intracoronary thrombolysis for acute myocardial infarction. Am Heart J 1983; 105:26.</a></li><li><a class="nounderline abstract_t">Zipes DP. The clinical significance of bradycardic rhythms in acute myocardial infarction. Am J Cardiol 1969; 24:814.</a></li><li class="breakAll">Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).</li><li><a class="nounderline abstract_t">Topol EJ, Goldschlager N, Ports TA, et al. Hemodynamic benefit of atrial pacing in right ventricular myocardial infarction. Ann Intern Med 1982; 96:594.</a></li><li><a class="nounderline abstract_t">Goldberg RJ, Seeley D, Becker RC, et al. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. Am Heart J 1990; 119:996.</a></li><li><a class="nounderline abstract_t">Crimm A, Severance HW Jr, Coffey K, et al. Prognostic significance of isolated sinus tachycardia during first three days of acute myocardial infarction. Am J Med 1984; 76:983.</a></li><li><a class="nounderline abstract_t">Becker RC, Burns M, Gore JM, et al. Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participants. Am Heart J 1998; 135:786.</a></li><li><a class="nounderline abstract_t">JAMES TN. Myocardial infarction and atrial arrhythmias. Circulation 1961; 24:761.</a></li><li><a class="nounderline abstract_t">Wong CK, White HD, Wilcox RG, et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J 2000; 140:878.</a></li><li><a class="nounderline abstract_t">Crenshaw BS, Ward SR, Granger CB, et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30:406.</a></li><li><a class="nounderline abstract_t">Pizzetti F, Turazza FM, Franzosi MG, et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001; 86:527.</a></li><li><a class="nounderline abstract_t">Eldar M, Canetti M, Rotstein Z, et al. Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. SPRINT and Thrombolytic Survey Groups. Circulation 1998; 97:965.</a></li><li><a class="nounderline abstract_t">Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 2009; 30:1038.</a></li><li><a class="nounderline abstract_t">Jons C, Jacobsen UG, Joergensen RM, et al. The incidence and prognostic significance of new-onset atrial fibrillation in patients with acute myocardial infarction and left ventricular systolic dysfunction: a CARISMA substudy. Heart Rhythm 2011; 8:342.</a></li><li><a class="nounderline abstract_t">Pedersen OD, Bagger H, Køber L, Torp-Pedersen C. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J 1999; 20:748.</a></li><li><a class="nounderline abstract_t">Behar S, Zahavi Z, Goldbourt U, Reicher-Reiss H. Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. SPRINT Study Group. Eur Heart J 1992; 13:45.</a></li><li><a class="nounderline abstract_t">Hod H, Lew AS, Keltai M, et al. Early atrial fibrillation during evolving myocardial infarction: a consequence of impaired left atrial perfusion. Circulation 1987; 75:146.</a></li><li><a class="nounderline abstract_t">Sakata K, Kurihara H, Iwamori K, et al. Clinical and prognostic significance of atrial fibrillation in acute myocardial infarction. Am J Cardiol 1997; 80:1522.</a></li><li><a class="nounderline abstract_t">Celik S, Erdöl C, Baykan M, et al. Relation between paroxysmal atrial fibrillation and left ventricular diastolic function in patients with acute myocardial infarction. Am J Cardiol 2001; 88:160.</a></li><li><a class="nounderline abstract_t">Nagahama Y, Sugiura T, Takehana K, et al. The role of infarction-associated pericarditis on the occurrence of atrial fibrillation. Eur Heart J 1998; 19:287.</a></li><li><a class="nounderline abstract_t">Zahler D, Merdler I, Rozenfeld KL, et al. C-Reactive Protein Velocity and the Risk of New Onset Atrial Fibrillation among ST Elevation Myocardial Infarction Patients. Isr Med Assoc J 2021; 23:169.</a></li><li><a class="nounderline abstract_t">Kramer RJ, Zeldis SM, Hamby RI. Atrial fibrillation--a marker for abnormal left ventricular function in coronary heart disease. Br Heart J 1982; 47:606.</a></li><li><a class="nounderline abstract_t">Danchin N, Fauchier L, Marijon E, et al. Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: data from the FAST-MI register. Heart 2010; 96:1809.</a></li><li><a class="nounderline abstract_t">Køber L, Bloch Thomsen PE, Møller M, et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 2000; 356:2052.</a></li><li><a class="nounderline abstract_t">Cameron A, Schwartz MJ, Kronmal RA, Kosinski AS. Prevalence and significance of atrial fibrillation in coronary artery disease (CASS Registry). Am J Cardiol 1988; 61:714.</a></li><li><a class="nounderline abstract_t">Axelrod M, Gilutz H, Plakht Y, et al. Early Atrial Fibrillation During Acute Myocardial Infarction May Not Be an Indication for Long-Term Anticoagulation. Angiology 2020; 71:559.</a></li><li><a class="nounderline abstract_t">Ganz LI, Friedman PL. Supraventricular tachycardia. N Engl J Med 1995; 332:162.</a></li><li><a class="nounderline abstract_t">Konecke LL, Knoebel SB. Nonparoxysmal junctional tachycardia complicating acute myocardial infarction. Circulation 1972; 45:367.</a></li><li><a class="nounderline abstract_t">Knoebel SB, Rasmussen S, Lovelace DE, Anderson GJ. Nonparoxysmal junctional tachycardia in acute myocardial infarction: computer-assisted detection. Am J Cardiol 1975; 35:825.</a></li><li><a class="nounderline abstract_t">Berisso MZ, Ferroni A, Molini D, Vecchio C. [Supraventricular tachyarrhythmias during acute myocardial infarction: short- and mid-term clinical significance, therapy and prevention of relapse]. G Ital Cardiol 1991; 21:49.</a></li><li><a class="nounderline abstract_t">Bigger JT Jr. Digitalis toxicity. J Clin Pharmacol 1985; 25:514.</a></li><li><a class="nounderline abstract_t">Kastor JA, Yurchak PM. Recognition of digitalis intoxication in the presence of atrial fibrillation. Ann Intern Med 1967; 67:1045.</a></li></ol></div><div id="topicVersionRevision">Topic 82 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4164117" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Gastrointestinal observations in rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4177159" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Incidence, significance, and management of early bradyarrhythmia complicating acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4551931" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Bradyarrhythmias in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12621138" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Use of the electrocardiogram in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6849238" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Reperfusion arrhythmia: a marker of restoration of antegrade flow during intracoronary thrombolysis for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5360234" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The clinical significance of bradycardic rhythms in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5360234" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The clinical significance of bradycardic rhythms in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7073152" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hemodynamic benefit of atrial pacing in right ventricular myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2330889" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6731469" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prognostic significance of isolated sinus tachycardia during first three days of acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9588407" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14451030" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Myocardial infarction and atrial arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11099991" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9247512" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11602545" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9529264" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. SPRINT and Thrombolytic Survey Groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19109347" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21093611" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The incidence and prognostic significance of new-onset atrial fibrillation in patients with acute myocardial infarction and left ventricular systolic dysfunction: a CARISMA substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10329066" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1577030" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. SPRINT Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3791600" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Early atrial fibrillation during evolving myocardial infarction: a consequence of impaired left atrial perfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9416928" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical and prognostic significance of atrial fibrillation in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11448413" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Relation between paroxysmal atrial fibrillation and left ventricular diastolic function in patients with acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9519323" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The role of infarction-associated pericarditis on the occurrence of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33734630" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : C-Reactive Protein Velocity and the Risk of New Onset Atrial Fibrillation among ST Elevation Myocardial Infarction Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7082508" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Atrial fibrillation--a marker for abnormal left ventricular function in coronary heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20965993" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: data from the FAST-MI register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11145491" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3258467" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prevalence and significance of atrial fibrillation in coronary artery disease (CASS Registry).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32103687" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Early Atrial Fibrillation During Acute Myocardial Infarction May Not Be an Indication for Long-Term Anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7800009" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5009481" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Nonparoxysmal junctional tachycardia complicating acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1093374" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Nonparoxysmal junctional tachycardia in acute myocardial infarction: computer-assisted detection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2055377" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : [Supraventricular tachyarrhythmias during acute myocardial infarction: short- and mid-term clinical significance, therapy and prevention of relapse].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3905880" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Digitalis toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4860764" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Recognition of digitalis intoxication in the presence of atrial fibrillation.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
